Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-03-10

Clinical Trial Update: Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating NOV-002 with carboplatin in chemotherapy-resistant ovarian cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CARBOPLATIN (Carboplatin)
  • NOV-002

Snippet

Sponsor: Cellectar Biosciences, Inc. | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-03-10